Stryker Corporation (SYK)
Sales Growth, Strategic Acquisitions Drive Stryker Higher
Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.
Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business
SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.
SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans
SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.
Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript
Stryker Corporation (NYSE:SYK ) Q4 2024 Earnings Conference Call January 28, 2025 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Andy Pierce - Group President of MedSurg & Neurotechnology Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Matthew O'Brien - Piper Sandler Companies Shagun Singh - RBC Matthew Miksic - Barclays Michael Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Josh Jennings - TD Cowen Danielle Antalffy - UBS Equities Michael Polark - Wolfe Research Operator Welcome to the Fourth Quarter 2024 Stryker Earnings Call. My name is Luke, and I'll be your operator for today's call.
Stryker (SYK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates
Stryker (SYK) came out with quarterly earnings of $4.01 per share, beating the Zacks Consensus Estimate of $3.87 per share. This compares to earnings of $3.46 per share a year ago.
Stryker forecasts 2025 profit above estimates on robust demand for surgical devices
Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices.
Overlooked Stock: SYK
Stryker Corp. (SYK) ticked higher after hours after the medical tech company posted an earnings beat. George Tsilis turned to how a rally from this mostly unseen stock reflects the healthcare industry.
Strong Segmental Performance to Drive Stryker's Q4 Earnings?
SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?
Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive with a PEG ratio around 3, but the company's consistent performance and market leadership justify a premium valuation. Stryker's strong company culture, impressive ROIC, and substantial insider ownership indicate a durable competitive advantage and a bright future.
